Business Context and Reporting Period
This Form 6-K filing by Sify Technologies Limited covers the month of June 2025, with a specific reporting date of June 10, 2025. The document addresses a corporate governance issue regarding the resignation of an independent director and the subsequent non-compliance with Nasdaq listing standards.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance and board composition rather than financial performance.
Material Changes
- Board Resignation: Dr. Ajay Kumar, an independent director, member of the Audit Committee, and Chairman of the Compensation/Nomination and Remuneration Committee, resigned on May 21, 2025, to assume a constitutional responsibility ordered by the President of India.
- Board Composition: Following the resignation, the Board consists of three independent directors and three non-independent directors. The Audit Committee now comprises only two independent directors.
- Regulatory Status: The Company notified Nasdaq of non-compliance with Listing Rule 5605(b)(1) (majority independent directors) and Rule 5605(c)(2) (minimum three audit committee members).
Guidance, Outlook, and Risks
Cure Period: Nasdaq has granted a cure period to regain compliance. This period lasts until the earlier of the next annual shareholders' meeting or May 15, 2026. If the next annual meeting occurs before November 11, 2025, compliance must be evidenced by November 11, 2025.
Management Action: The Company is actively identifying and evaluating candidates to appoint a new independent director to fill the vacancies and regain compliance.
Risks and Contingencies:
- There is no assurance the Company will regain compliance with independent director requirements or maintain other listing standards.
- Failure to comply by the end of the cure period will result in a notice of delisting.
- The Company may appeal a delisting determination to a Nasdaq Hearings Panel.
- The notice has no immediate effect on the listing or trading of the Company's ADSs on the Nasdaq Capital Market.
Key Facts for Investor Verification
- Verify the timeline for the Company's next annual shareholders' meeting to determine the exact deadline for regaining compliance.
- Monitor announcements regarding the appointment of a new independent director to the Board and Audit Committee.
- Confirm the continued trading status of ADSs on the Nasdaq Capital Market during the cure period.
- Review any future filings for updates on the Company's ability to meet Nasdaq Listing Rule 5605 requirements.